Epidiolex

GW Pharmaceuticals PLC (NASDAQ: GWPH) produces the only cannabis-derived drug approved by the Food and Drug Administration: Epidiolex, for the treatment of seizures in children.  GW is a major pharmaceutical company and shouldn't be grouped together with "sketchy" weed...

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) reported second-quarter earnings and revenue Tuesday that blew past estimates, sending its shares solidly higher Wednesday. The Analysts Morgan Stanley analyst David Lebowitz maintained an Overweight rating on GW Pharma and increased the price...

GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH), the British manufacturer of the CBD drug Epidiolex, said Tuesday that the medication posted net sales of $68.4 million during the quarter and $101.9 million in the first half of 2019.  GW Pharma posted $72 million in revenue in the quarter versus $3.3...

The Food and Drug Administration says it knows there’s demand for cannabis products, but says it's taking a “science-based” approach to determine their safety and efficacy as it considers how to handle their legality. What To Know The FDA recently opened a public docket on...

GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) opened higher by 8 percent Tuesday after posting positive results from its Phase 3 Epidiolex trial and second-quarter earnings beats. Here’s what analysts are saying. Epidiolex Sales GW Pharma closed out its first full quarter of Epidiolex sales...

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH)'s cannabidiol drug Epidiolex is inching closer to another FDA approval.  What Happened GW Pharma reported Monday after the close with positive topline results from a Phase 3 study of Epidiolex in the treatment of seizures associated with...

Zogenix, Inc. (NASDAQ: ZGNX), which develops therapies for rare diseases, said Monday afternoon the FDA issued a refusal to file letter regarding its NDA for Fintepla, chemically fenfluramine hydrochloride, which is being evaluated for the treatment of seizures associated with Dravet syndrome. The...

Cannabis stocks have been red-hot so far in 2019, and Piper Jaffray analyst Michael Lavery said Monday that the outlook for medical cannabis is brighter than ever. Lavery recently met with a pain specialist to determine how much of an impact medical marijuana could have on the business of pain...

Following its results for the first quarter of fiscal 2019, analysts at Cantor Fitzgerald provided an update about GW Pharmaceuticals plc (NASDAQ: GWPH). The Analyst Cantor Fitzgerald analysts Elemer Piros and Kristen Kluska reiterated the Overweight rating and $193 price target on GW...

GW Pharmaceuticals plc (NASDAQ: GWPH) reported its financial results Tuesday for the first quarter of fiscal 2019. The company reported revenue growth of  67.5 percent. One highlight: the report includes sales of the company's Epidiolex drug, which last year became the first cannabis-based...

Investors in GW Pharmaceuticals PLC (NASDAQ: GWPH) may need to sit through some short-term volatility as sales of the company's newly approved drug ramp up slowly because of insurance coverage issues, says the author of The 420 Investor. Alan Brochstein, who is a founding partner of New...

Bank of America Merrill Lynch doubled down on its bullish thesis for GW Pharmaceuticals plc (NASDAQ: GWPH) and its flagship Epidiolex drug after attending the American Epilepsy Society's annual meeting. The Analyst Analysts Tazeen Ahmad maintained a Buy on GW Pharma with a $190 price...

GW Pharmaceuticals plc (NASDAQ: GWPH) Epidiolex drug and earlier-stage programs Sativex and CBDV will represent major catalysts for the stock in the near-term, in Cantor Fitzgerald's view.  The Analyst Analyst Elemer Piros reiterated an Overweight on GW Pharmaceuticals with a $211 price...

GW Pharmaceuticals plc (NASDAQ: GWPH) reported financial results for its fiscal fourth quarter 2018. Compared to analysts' consensus estimates, the company reported a better-than-expected net loss, but its top line missed the expectations. What Happened For the quarter ended Sept. 30, GW...

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) announced incremental positive news on its lead cannabinoid product candidate Epidiolex, sending the stock higher. What Happened GW Pharma announcedpositive results for a second, late-stage study that evaluated its Epidiolex oral solution for treatment...